I wonder if somebody has found more than one bunsen burner which PYC own at the car boot - thought about selling them at a great loss this afternoon and then wow. Might not continue but would be nice if whoever was as stupid as I was at the time of my purchase could make a little profit. India here we come may be.

Stmnt re Share Price Movement
RNS
RNS Number : 5131J
Physiomics PLC
07 August 2012



Physiomics plc



(the "Company" or "Physiomics")



Share Price Movement

Following the recent movement in its share price today, the Company notes the announcement made by Sareum plc ("Sareum") as to its advanced stage negotiations; and the rumour and speculation that this will impact Physiomics.

There are no agreements in existence between Sareum and Physiomics which will have a material impact on the Company.

On the up..

Flipping more than doubled - I had actually forgotten these existed and don't hold anymore. Shame.

Physiomics sign up large new customer

StockMarketWire.com

Physiomics, the Oxford based systems biology company, has signed a contract with its first large pharma customer to supply cardiac toxicity risk modelling services.

The initial contract runs for 12 months and involves a number of compounds which will be put through one of our cardiac toxicity models.

The company hope that this will lead to a more extensive interaction in future as the benefits of this strategy become apparent.

Cardiac toxicity is a well-known risk factor in drug development. Candidate drugs are routinely screened using laboratory-based tests, which are not always predictive, are costly and time consuming.

Physiomics has developed a suite of virtual cardiotox platforms which can be used to rapidly assess risk at a relatively early stage of development, for minimal cost per compound. Dr Mark Chadwick, CEO of Physiomics, commented: "We are very pleased to have signed up our first large pharma customer for this important new model. Our cardiotox platform has generated significant interest particularly amongst large pharma companies and regulatory agencies."



At 12:36pm: (LON:PYC) Physiomics share price was +0.12p at 0.23p

good revenue producing news at last - drugcard now released.............

DrugCARD launch
RNS Number : 2008U
Physiomics PLC
28 November 2013



Physiomics plc

("Physiomics") or ("the Company")



Physiomics launches new DrugCARD® database for oncology researchers and clinicians





Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has now launched its Drug Combinations and Regimens database. DrugCARD® collates curated publicly available pre-clinical and clinical drug regimen data into one easily searchable tool. It also contains further clinical data and analysis which is only available through the collaboration with Pharmacometrics.



DrugCARD® currently contains clinical data for over 160 drugs used in over 700 regimens. Standards of care, novel targeted small molecule agents and biologics are all represented.



Using DrugCARD®, researchers, who will access the database on a subscription basis, will be able to rapidly compare regimen data and outcomes across a number of studies, saving them time and effort when literature-hunting. The Pharmacometrics data also adds pre-clinical and clinical modelling information not available elsewhere.



DrugCARD® can be accessed at: www.drug-card.co.uk



Dr Mark Chadwick, CEO of Physiomics, commented:

"We are delighted to release the DrugCARD® database. This new product will allow us to rapidly access a wide range of target customers, including clinicians who have not previously been engaged and who would also benefit from using our emerging Virtual Tumour Clinical platform."

moving

rns out - just signed a 'substantial contract'.........................

[ Post Moderated ]

[ Post Moderated ]